Related Experiment Video
Updated: Sep 30, 2025

08:51
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
9.2K
Multiple sclerosis cortical lesion detection with deep learning at ultra-high-field MRI
Francesco La Rosa1,2,3, Erin S Beck3,4, Josefina Maranzano5,6
1Signal Processing Laboratory (LTS5), Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne.
NMR in Biomedicine
|March 17, 2022
Summary
Automating multiple sclerosis (MS) cortical lesion (CL) detection using the CLAIMS deep learning framework significantly reduces manual segmentation time and improves accuracy. CLAIMS demonstrates superior performance compared to existing methods, aiding MS diagnosis with 7T MRI.
Area of Science:
- Neuroimaging
- Artificial Intelligence
- Medical Diagnostics
Background:
- Manual segmentation of multiple sclerosis cortical lesions (CLs) is time-consuming and suffers from moderate inter-rater reliability.
- Accurate CL detection is crucial for MS diagnosis and monitoring.
Purpose of the Study:
- To develop and evaluate a deep-learning framework (CLAIMS) for automated detection and classification of MS CLs using 7T MRI.
- To compare CLAIMS performance against state-of-the-art methods and manual segmentation.
Main Methods:
- Developed CLAIMS, a deep learning framework for CL detection and classification.
- Evaluated CLAIMS on two independent 7T MRI datasets with varying resolutions and contrasts.
- Compared CLAIMS with MSLAST, a state-of-the-art technique, using lesion-wise detection rates and correlation with disability measures.
Main Results:
- CLAIMS achieved a CL true positive rate of 74% with a 30% false positive rate, comparable to multi-contrast models.
- Detection rates were 83% for leukocortical, 70% for subpial, and 53% for intracortical lesions.
- CLAIMS outperformed MSLAST on an external dataset, showing a 71% lesion-wise detection rate versus 48% for MSLAST.
Conclusions:
- The CLAIMS framework provides accurate and automated detection of MS CLs using 7T MRI.
- CLAIMS demonstrates superior generalizability and performance across different scanners and protocols compared to existing methods.
- CLAIMS has the potential to support clinical decisions in the diagnosis and differential diagnosis of MS.

